SciRhom

Executive Summary

SciRhom GmbH is a German biotech company pioneering first-in-class humanized antibodies targeting iRhom2, a crucial regulator of the enzyme TACE (ADAM17). By inhibiting iRhom2, SciRhom aims to block TACE-mediated shedding of inflammatory cytokines such as TNFα, offering a novel approach to treating autoimmune diseases. The company was founded in 2016 and is based in Hamburg, with close scientific collaboration with Prof. Carl Blobel at the Hospital for Special Surgery in New York. Currently in the preclinical stage, SciRhom has generated promising data demonstrating the therapeutic potential of its anti-iRhom2 antibodies in various disease models. The company's lead program addresses a key node in inflammation, potentially providing a safer and more targeted alternative to broad TNFα inhibitors. SciRhom is advancing its candidate toward IND-enabling studies, with a focus on completing necessary toxicology and manufacturing milestones. The preclinical pipeline positions SciRhom to enter clinical development within the next 12–18 months, pending regulatory filings and additional funding. With a novel mechanism and strong scientific rationale, SciRhom represents a compelling yet early-stage opportunity in the autoimmune space.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling toxicology studies70% success
• Q1 2027Filing of Investigational New Drug (IND) application60% success
• Q2 2027Initiation of first-in-human Phase 1 clinical trial50% success